Research Center for Medicinal Chemistry, Korea Research Institute of Chemical Technology, Yuseong-gu, Daejeon 305-343, Republic of Korea.
Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6. doi: 10.1016/j.bmcl.2013.10.036. Epub 2013 Oct 30.
G-protein-coupled receptor kinase (GRK)-2 and -5 are emerging therapeutic targets for the treatment of cardiovascular disease. In our efforts to discover novel small molecules to inhibit GRK-2 and -5, a class of compound based on 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine was identified as a novel hit by high throughput screening campaign. Structural modification of parent benzoxazole scaffolds by introducing substituents on phenyl displayed potent inhibitory activities toward GRK-2 and -5.
G 蛋白偶联受体激酶(GRK)-2 和 -5 是治疗心血管疾病的新兴治疗靶点。在我们努力发现新型小分子来抑制 GRK-2 和 -5 的过程中,通过高通量筛选发现了一类基于 3-(苯并[d]恶唑-2-基)-5-(1-(哌啶-4-基)-1H-吡唑-4-基)吡啶-2-胺的化合物,这是一种新型命中物。通过在苯环上引入取代基对母体苯并恶唑骨架进行结构修饰,显示出对 GRK-2 和 -5 的强大抑制活性。